Physician profile
Audrey A Forka
NPI 1780087213
$4,442.98
in general payments reported to CMS, 2019-2025
25 companies · $923 in 2025
The $923 reported for 2025 was more than what 79% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $888 · 2022: $741 · 2023: $716 · 2024: $1,175 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,814.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $459.14 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $425.22 | 2021-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $420.99 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $359.27 | 2021-2025 | Caplyta |
| Alkermes, INC. | $356.42 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $334.17 | 2021-2025 | Ingrezza |
| Corium, LLC | $325.33 | 2022-2025 | Azstarys |
| Lundbeck LLC | $322.57 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $248.59 | 2021-2024 | Trintellix |
| Ironshore Pharmaceuticals INC. | $190.15 | 2022-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $188.54 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Janssen Pharmaceuticals, INC | $168.73 | 2023-2025 | Invega Sustenna, Spravato |
| Tris Pharma INC | $111.62 | 2021-2024 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $95.21 | 2022-2025 | Quviviq, Quviviq |
| Teva Pharmaceuticals USA, INC. | $84.79 | 2022-2025 | Austedo Xr, Austedo Xr |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $67.91 | 2024 | Hetlioz, Fanapt |
| E.R. Squibb & Sons, L.L.C. | $53.16 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $39.27 | 2025 | Auvelity |
| Sage Therapeutics, LLC | $37.65 | 2024 | |
| Collegium Pharmaceutical, INC. | $37.19 | 2025 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $35.89 | 2022 | |
| Janssen Scientific Affairs, LLC | $26.45 | 2025 | Invega Sustenna |
| Indivior INC. | $24.10 | 2022 | |
| Merck Sharp & Dohme LLC | $16.20 | 2023 | Belsomra |
| Bausch Health US, LLC | $14.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audrey Forka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.